Ponatinib promotes a G(1) cell-cycle arrest of merlin/NF2-deficient human schwann cells

Neurofibromatosis type 2 (NF2) is a genetic syndrome that predisposes individuals to multiple benign tumors of the central and peripheral nervous systems, including vestibular schwannomas. Currently, there are no FDA approved drug therapies for NF2. Loss of function of merlin encoded by the NF2 tumo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Petrilli, Alejandra M, Garcia, Jeanine, Bott, Marga, Plati, Stephani Klingeman, Dinh, Christine T, Bracho, Olena R, Yan, Denise, Zou, Bing, Mittal, Rahul, Telischi, Fred F, Liu, Xue-Zhong, Chang, Long-Sheng, Bradley, D Welling, Copik, Alicja J, Fernández-Valle, Cristina
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5458238/
https://ncbi.nlm.nih.gov/pubmed/28427224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15912
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky